Overriding imatinib resistance with a novel ABL kinase inhibitor - Wikidata - thesis-toulmin - TriplyDB

Overriding imatinib resistance with a novel ABL kinase inhibitor

Overriding imatinib resistance with a novel ABL kinase inhibitor

http://www.wikidata.org/entity/Q30014844

about

Genome of the human hookworm Necator americanus A secreted tyrosine kinase acts in the extracellular environment Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Latent bone metastasis in breast cancer tied to Src-dependent survival signals Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues A conserved protonation-dependent switch controls drug binding in the Abl kinase Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head Hematologic malignancies during pregnancy: A review Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors Rational approaches to improving selectivity in drug design The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution.Mechanisms of drug resistance in kinases.Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain Overcoming mutation-based resistance to antiandrogens with rational drug design Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism Effect of cellular quiescence on the success of targeted CML therapy Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia Allosteric interactions between the myristate- and ATP-site of the Abl kinase

P2860

25e3e91d094103f15c22ff67f4ae04c3a66ea075 674c8873f9283815ea61690f9e003e54bbfd22cb 79606d50a125ebe7516e30a96bb47a9a76608ae9 7a9d801a2c5b12c81f33223e31e425cc98c96961 7d7f68218cc884c028d9fc1ee272e9d7a66eaca3 986cb6debd449e8a1f039b4d40c1dc831ab125e7 b65f57990d37971600f0c6a4b02a5527b684b458 c1da356bc23895cf31d0341bcfdbee371ecf6758 df99e94e94acdf6c0944481445a241602367dadb

P248

Q22122067-02F98F78-207B-4FC9-9446-B6DEF1F63D6F Q24303065-6272C369-2163-4DE2-B0F7-BF32F1CBFE73 Q24622397-B1615CF3-732C-4AE1-AB83-C9F8427F4681 Q24648017-C5619A75-6697-4EB2-BDA3-C10E924C9065 Q24648828-D6744CF0-460D-40F3-92FC-C31C22701500 Q24653036-ECA39F4C-8D2D-43A3-9E8D-7461CEFB5F41 Q24657421-C2B5FCD1-C2CC-4ADB-8E41-47CFDE9C3F82 Q24681743-3887BA03-E22E-44F6-AB6C-858DAEF7D082 Q24794765-911E0B59-B6CA-446E-A3D1-DEEF9018316A Q24794815-AD91BE1E-5D43-4632-87BE-7A82F1B1E28F Q26740587-CA847D8E-2A36-4DC2-A3B7-186D8A0B01F2 Q26766299-EC5A24B3-F6CF-47E7-99BF-DE86F27EA504 Q26774957-68D3125D-81E1-4772-92E9-C0644EB5775A Q26824310-7DEBC7F4-8AFB-4180-963A-BB24BD8EE626 Q26828528-6EB5F654-73E2-4B06-B7DF-C621EC63B497 Q26849792-A71CD596-675B-4941-A24F-DD8BF5C27A01 Q26865357-353699CB-05C5-4B41-A1C0-0E6CE52C9103 Q26866312-60E55294-CE4E-4107-9D85-429BCDFE1116 Q27330347-B84B755A-6342-4D61-91DE-E1E18E08A293 Q27649203-4688F3A6-0530-4054-ACDE-AF76CE5727C9 Q27650325-4443492F-2C64-44E7-9E0C-FE2A3F3A8265 Q27652762-C950AF52-F226-4FB8-A22A-932175F4D542 Q27654059-E4472D79-9D5A-4B42-8C52-B4B2CB1B772D Q27658951-2CAB223D-DF11-4423-A094-D49AA32012E9 Q27660281-90E2CE84-5EBC-41E9-95ED-73473950C669 Q27667482-F94604E7-E701-42C6-B9F5-A122ACE7BDAD Q27675279-17C9D05F-B6A5-4191-A8D7-EFCAD5B40131 Q27690285-34EA153E-FF72-4A3D-BC43-EAA788D0D5F9 Q27692567-4C56CECD-C2B6-404D-A4F8-707CFA4ED12D Q27712065-3F09A90F-D591-43E4-86FE-DEA951053B58 Q27851628-500048A5-8216-40A7-8997-B7AD908DEBB6 Q27852657-23A79D97-4A5A-4DB3-9B23-C96D05EA9E1E Q27865182-9D7CADC9-A34D-45CA-AED1-1174D10DDE29 Q28044590-CEFA02B3-3611-49B5-96C9-B45765582757 Q28254233-4270F75A-75D7-4DAA-BB74-2076939D7BF9 Q28275023-7A58C2F8-9F54-4540-A8DB-DACBD08B59BC Q28469312-BA3E6511-1E50-4F9C-B198-7230F25BDC95 Q28473957-0353D617-6E13-4DA3-B690-E83A1EEC798E Q28474737-A24BFDA3-0B0A-4CF0-B42D-B24502B980F3 Q28476718-5166AA50-3A51-4FBC-A028-9FECFF39780C

P2860

Overriding imatinib resistance with a novel ABL kinase inhibitor

http://www.wikidata.org/entity/Q30014844

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Overriding imatinib resistance with a novel ABL kinase inhibitor

@ast

Overriding imatinib resistance with a novel ABL kinase inhibitor

@en

type

label

Overriding imatinib resistance with a novel ABL kinase inhibitor

@ast

Overriding imatinib resistance with a novel ABL kinase inhibitor

@en

prefLabel

Overriding imatinib resistance with a novel ABL kinase inhibitor

@ast

Overriding imatinib resistance with a novel ABL kinase inhibitor

@en

P1433

Q30014844-530437D0-E492-4B23-9D72-8899E4715B43

P1476

Q30014844-FD978196-5B0C-43F2-A9B2-EACBD2C63293

P2093

Q30014844-2C70EBFF-D207-4444-B6D5-DEC29EA57763

Q30014844-38A69C5C-7E15-432B-B0AD-9B0D386647F9

Q30014844-6141A759-B540-462F-8504-EE822A67924B

Q30014844-796F9C80-861B-491D-B1A9-BBB6451F5337

Q30014844-DE36F61D-C2CB-49ED-A628-4A61B88CE09C

Q30014844-F545826A-0A67-4648-A666-8386C5B6B7C6

P304

Q30014844-1D419CBD-C2D1-474E-BDAC-2CB8CF71987D

P31

Q30014844-DA6FDF74-9E0C-4C06-A47C-361DB78D4181

P3181

Q30014844-26E943FD-18AA-428F-B1EA-E9FC401FB8E9

P356

Q30014844-290A54DB-468F-41F3-AD74-7E6E975783D7

P407

Q30014844-14320A8E-EFBD-4350-92CA-101D8C4BAC87

P433

Q30014844-F474D673-C91E-4F17-AA2C-B3C10FD2B98A

P478

Q30014844-C995DC52-171E-458B-9211-EACA65B3BF55

P577

Q30014844-E5F9FCB4-B208-485F-BCDB-70FF972B0821

P5875

Q30014844-94070BE2-D392-4545-A9A9-00F2CE2A07FE

P698

Q30014844-D1AB69DD-0262-4960-8E11-3EA71BA20E3D

P3181

P356

SCIENCE.1099480

P1433

P1476

Overriding imatinib resistance with a novel ABL kinase inhibitor

@en

P2093

Chen P

http://www.w3.org/2001/XMLSchema#string

Lee FY

http://www.w3.org/2001/XMLSchema#string

Norris D

http://www.w3.org/2001/XMLSchema#string

Sawyers CL

http://www.w3.org/2001/XMLSchema#string

Shah NP

http://www.w3.org/2001/XMLSchema#string

Tran C

http://www.w3.org/2001/XMLSchema#string

P304

399-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2263135

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1099480

http://www.w3.org/2001/XMLSchema#string

P407

P433

5682

http://www.w3.org/2001/XMLSchema#string

P478

305

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8452266

http://www.w3.org/2001/XMLSchema#string

P698

15256671

http://www.w3.org/2001/XMLSchema#string